Tegoprazan
Phase 3Small molecule
Tegoprazan is a small molecule that works as a Potassium-Transporting Atpase Blocker.[2] It is being investigated across 9 indications, with its most advanced program in Phase 3.[1]
Tegoprazan is one of 230 small molecule programs targeting Helicobacter Pylori Infection. It is currently in Phase 3.
9
Indications
38
Total Trials
12
Active Trials
229
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
242 competitors in Efficacy and Safety
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Rinvoq
AbbViePhase 3
Savaysa
Daiichi SankyoPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Rapamune
PPrism Pharmaceuticals
Phase 3
Rilutek
AAzurity Pharmaceuticals
Phase 3
Kineret
SSwedish Orphan Biovitrum
Phase 3
UPLIZNA
HHorizon Therapeutics Ireland DAC
Phase 3
Tegoprazan
SShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Phase 3
Becotatug Vedotin
FFudan University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Efficacy and Safety4 trials
Oral4 trials
Interaction3 trials
Clopidogrel3 trials
17 more indications
Randomized Controlled Trial1 trial
Atorvastatin1 trial
TED1 trial
Hepatic Impairment1 trial
Tics1 trial
Bismuth Quadruple Therapy1 trial
Esophagitis1 trial
Safety and Efficacy1 trial
Adult1 trial
General Anesthesia1 trial
Laryngopharyngeal Reflux1 trial
GERD (Gastroesophageal Reflux Disease)1 trial
Ischemic stroke1 trial
Unspecified5 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tegoprazan. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details